Toutes les études
RecrutementPHASE3INTERVENTIONNEL

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

This research study is testing a new medicine called zeleciment basivarsen (DYNE-101) for people with Myotonic Dystrophy Type 1 (also known as DM1 or Steinert Disease). The main goal is to find out if this medicine is effective at treating the condition, how safe it is, and if people can take it without too many side effects. Participants will be split into groups; one group will receive the new study medicine and the other will receive a dummy medicine (called a placebo) that looks the same but contains no active drug. This comparison helps us understand the true effects of the new medicine. The study will last for a total of nearly a year and a half, including initial checks, the treatment period, and follow-up.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Dyne Therapeutics
Objectif d'inscription
150
Démarrer
14 mai 2026
Achèvement estimé
01 Jan 2029

De quoi parle cette étude ?

This study is investigating a new potential treatment for Myotonic Dystrophy Type 1 (DM1), a condition that can affect muscles and other parts of the body. The experimental medicine is named zeleciment basivarsen, also known by its research code DYNE-101. Researchers want to understand if this medicine can make a positive difference for people living with DM1. They will specifically look at three main things: how well it works (its 'efficacy'), how safe it is for people to take, and whether people can tolerate it without experiencing difficult side effects.

To properly test the medicine, the study will involve a 'placebo-controlled' period. This means some participants will receive the actual study medicine, and others will receive a 'placebo' – a substance that looks exactly like the medicine but has no active ingredients. Comparing results between these two groups helps doctors determine if any changes or improvements are genuinely due to the new medicine or if they might have happened anyway. After this main treatment phase, there's also a period for long-term follow-up.

An important safeguard in this study is an Independent Data Monitoring Committee. This group is made up of experts who are not involved in running the study. They will regularly check the safety information gathered from all participants. Their role is to ensure everyone's well-being throughout the trial and to make recommendations if any safety concerns arise. This independent check adds an extra layer of protection for participants.

Points clés

  • This study evaluates a new medicine (DYNE-101) for Myotonic Dystrophy Type 1.
  • It aims to check the medicine's effectiveness, safety, and how well people tolerate it.
  • Participation involves screening, a treatment period (with either the drug or a placebo), and follow-up.
  • An independent committee is overseeing participant safety throughout the study.
  • The total time commitment for the study is approximately 1.5 years.

Qui peut être éligible ?

To join this study, your doctor will need to confirm you have Myotonic Dystrophy Type 1 (DM1) with a specific genetic test result showing a 'trinucleotide repeat size' greater than 100. This genetic test confirms the type of DM1. You must also be able to walk 10 meters and get up from a chair 5 times by yourself. You can use walking aids like insoles or ankle supports if they don’t go above your ankle.

Your body mass index (BMI) needs to be under 35. You cannot join if you have been diagnosed with the serious 'congenital' form of DM1 or if you've had major surgery in the last 12 weeks, unless it was for a pacemaker or defibrillator. Also, if you've recently taken certain diabetes or weight-loss medicines (like semaglutide, dulaglutide, liraglutide, exenatide, or tirzepatide), you might need to wait a specific period before being able to participate.

There might be other health requirements or reasons why you can or cannot join. The study team will review all your medical information carefully to see if this study is suitable for you.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Do I have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) from a genetic test?
  2. Can I walk 10 meters and stand up from a chair 5 times on my own (with minor aids if needed)?
  3. Is my Body Mass Index (BMI) below 35?
  4. Have I avoided certain GLP-1/incretin medications (like Ozempic, Trulicity) recently?
  5. Have I had any major surgery in the last 12 weeks (excluding pacemaker/defibrillator)?
  6. Have I been diagnosed with 'congenital' DM1 (this would exclude me)?
  7. Am I aged 16 years or older?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, the study will have different stages. First, there's a 'Screening' period which can last up to 8 weeks. During this time, you'll have various tests and checks to make sure you meet all the criteria for joining the study. After screening, there’s a main 'Placebo-Controlled Period' which lasts for 48 weeks (just under a year). During this time, you will receive either the study medicine or the placebo. Finally, there's a 'Long-Term Extension Period' of 24 weeks (about 5 and a half months) to continue tracking your health and the medicine's effects. You will have regular visits to the clinic for assessments, which will include examinations, blood tests, and other specific checks related to your DM1. The exact number of visits will be explained by the study team, but throughout the entire study, you can expect to be involved for about a year and a half.

Risques et avantages potentiels

Taking part in a clinical trial may offer potential benefits, such as access to a new medicine that is not yet widely available and the chance to contribute to medical knowledge that could help others with DM1 in the future. However, there are also potential risks involved. You might experience side effects from the study medicine, or you might receive a placebo and therefore not get any active treatment. There may also be inconveniences from the study visits and procedures. You will be closely monitored, and an independent committee will regularly review safety data. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Emplacements (44)

  • UCSD - Altman Clinical and Translational Research Institute
    Code postal vérifié
    La Jolla, United States· Recrutement
  • UCLA Medical Center (Department of Neurology)
    Code postal vérifié
    Los Angeles, États-Unis· Recrutement
  • Stanford Neuroscience Health Center
    Code postal vérifié
    Palo Alto, United States· Recrutement
  • UF Health: University of Florida Clinical Research Center
    Code postal vérifié
    Gainesville, États-Unis· Recrutement
  • Rare Disease Research, LLC
    Code postal vérifié
    Atlanta, États-Unis· Recrutement
  • IU Health Neuroscience Center
    Code postal vérifié
    Indianapolis, États-Unis· Recrutement
  • Kennedy Krieger Institute
    Code postal vérifié
    Baltimore, États-Unis· Recrutement
  • Roy Blunt NextGen Precision Health Institute
    Code postal vérifié
    Columbia, United States· Recrutement
  • University of Rochester Medical Center
    Code postal vérifié
    Rochester, États-Unis· Recrutement
  • Rare Disease Research, LLC
    Code postal vérifié
    Hillsborough, United States· Recrutement
  • Houston Methodist Neurological Institute
    Code postal vérifié
    Houston, États-Unis· Recrutement
  • The University of Texas Health Science Center at San Antonio
    Code postal vérifié
    San Antonio, United States· Recrutement

Questions fréquentes

What is Myotonic Dystrophy Type 1 (DM1)?

DM1 is a genetic condition that mainly causes muscle problems, like weakness and stiffness, but can also affect other parts of the body.

What is zeleciment basivarsen (DYNE-101)?

It's a new medicine being tested in this study to see if it can treat Myotonic Dystrophy Type 1.

Que signifie 'contrôlé par placebo' ?

It means some people will get the real medicine, and others will get a 'dummy' medicine without active ingredients. This helps researchers compare the effects.

Combien de temps vais-je participer à l'étude ?

The study involves a screening period, a treatment period, and a follow-up period, lasting about one and a half years in total.

Saurai-je si je reçois le vrai médicament ou le placebo ?

During the main part of the study for ethical reasons, neither you nor your study doctor will know who is getting which. This is called 'blinding'.

Comment en savoir plus

Dyne Clinical Trials

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Efficacy, Safety, and Tolerability of Zeleciment Basivarsen … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.